AccuRna
AccuRna is a pioneering company specializing in the development of unique drug delivery systems (DDS) for nucleic acid therapeutics. Founded in 2015, their mission is to deliver innovative medicines through novel DDS platforms, aiming to eliminate the global bottleneck in nucleic acid drug development and provide effective treatments for refractory diseases. They focus on promoting therapeutic innovation using their robust DDS technology, which addresses challenges such as instability in blood, low cell permeability, immunogenicity, and poor delivery to target organs. The company actively engages in partnerships with pharmaceutical companies, academic institutions, and research organizations to advance nucleic acid therapeutics and foster collaborative R&D efforts.
Industries
Nr. of Employees
small (1-50)
Products
uPIC (unit Poly Ion Complex)
A drug delivery system for short chain nucleic acid therapeutics that stabilizes nucleic acids in the body, improving retention in blood and accumulation in tumors.
Polyplex micelle
A drug delivery system for long chain nucleic acid therapeutics, enhancing mRNA stability against RNase attack and bypassing immune recognition.
uPIC (unit Poly Ion Complex)
A drug delivery system for short chain nucleic acid therapeutics that stabilizes nucleic acids in the body, improving retention in blood and accumulation in tumors.
Polyplex micelle
A drug delivery system for long chain nucleic acid therapeutics, enhancing mRNA stability against RNase attack and bypassing immune recognition.
Services
Co-development and strategic alliance for nucleic acid drugs
Collaborative research and development agreements to apply a nucleic acid delivery platform to partner drug candidates.
Incubation and licensing of academic assets
In-licensing and incubation services to mature academic discoveries and enable alliances or licensing to industry partners.
Partnering engagement and feasibility studies
Structured engagement including feasibility studies and partnership discussions to evaluate application of delivery technologies to external assets.
Co-development and strategic alliance for nucleic acid drugs
Collaborative research and development agreements to apply a nucleic acid delivery platform to partner drug candidates.
Incubation and licensing of academic assets
In-licensing and incubation services to mature academic discoveries and enable alliances or licensing to industry partners.
Partnering engagement and feasibility studies
Structured engagement including feasibility studies and partnership discussions to evaluate application of delivery technologies to external assets.
Expertise Areas
- Drug delivery for nucleic acid therapeutics
- Nucleic acid therapeutic modalities (ASO, siRNA, miRNA, mRNA)
- Platform-based co-development with pharmaceutical partners
- Incubation and translation of academic research toward commercialization
Key Technologies
- Nucleic acid therapeutics (ASO, siRNA, miRNA, mRNA)
- Drug delivery system (DDS) platforms for nucleic acids
- Formulation and stabilization strategies for nucleic acids
- Targeted delivery to specific organs/tissues